Preview

Russian competition law and economy

Advanced search

Antitrust Compliance in the Pharmaceutical Industry: Problems and Prospects of Implementation

https://doi.org/10.47361/2542-0259-2021-4-28-52-59

Abstract

The article examines the background of legislative consolidation and the main problems of the introduction by pharmaceutical companies of a new legal institution for the prevention of violations of antimonopoly legislation — antimonopoly compliance, introduced by Federal Law No. 33-FL of March 1, 2020.
The definition of the concept and a brief description of the current state and trends in the development of the pharmaceutical industry in connection with the relations of competition are given.
The necessity of introducing antimonopoly compliance by pharmaceutical companies as a relatively independent part of pharmaceutical compliance as the most general (universal) tool for self-prevention of any offenses by the company itself and all its employees in connection with official activities is substantiated.
The main antimonopoly risks associated with the implementation of pharmaceutical companies’ economic activities are named. Typical examples of violations of antimonopoly legislation by pharmaceutical companies are considered.
The results of a sample survey of pharmaceutical industry representatives conducted by the author on their attitude to the introduction of antimonopoly compliance are presented.
Proposals have been formulated to amend the Code of Administrative Offences of the Russian Federation in order to create additional incentives for the implementation of antimonopoly compliance.

About the Author

M. А. Sdvizhkov
All-Russian State University of Justice (RLA of the Ministry of Justice of Russia)
Russian Federation

Mikhail A. Sdvizhkov

Azovskaya str., 2, bldg 1, Moscow, 117638



References

1. Gromova E. A. Anti-monopoly compliance: implementation issues // Jurist. 2017;17: 30—31 (In Russ.)

2. Rumyantseva Iu. N. Antimonopoly compliance as a part of the compliance program of the russian legislation implementation // Prologue: Law Journal. 2019;2(22): 53-56 (In Russ.), https://doi.org/10.21639/2313-6715.2019.2.8

3. Beigulenko S. A. Organization compliance of modern russian pharmaceutical corporations // Finansovye issledovania. 2016;1(50):12-19 (In Russ.)

4. Rodionova A.Yu. Specific features of distribution of pharmaceutical products in the russian federation // Economy and Business: Theory and Practice. 2021;42(74):110-115 (In Russ.), https://doi.org/10.24412/2411-0450-2021-4-2-110-115

5. Maksimov S. V., Rudaya T. Yu., Utarov K. A. Risk-based approach and pharmaceutical compliance in the sphere of state supervision of illegal circulation of medical products // Russian Journal of Legal Studies. 2019;6(2(19):150-157 (In Russ.)

6. Lisitsyn-Svetlanov A. G., Bashlakov-Nikolaev I. V., Zavarukhin V. P., Maksimov S. V. Cartelization of the Russian economy: the main causes, consequences, and ways of their elimination // Herald of the Russian Academy of Sciences. 2020;90(5):567-576, https://doi.org/10.1134/S1019331620050159

7. Nadezhda Sharavskaya. The pharmaceutical industry is always in the zone of increased attention of antimonopoly authorities // URL: https://fas.gov.ru/news/30088 (Accessed: 03.09.2021) (In Russ.)

8. Nezhnikova E. V., Maksimchuk M. V. Pharmaceutical industry in russia: problems and prospects of development // RUDN Journal Of Economics. 2019;27(1):102-112 (In Russ.), https://doi.org/10.22363/2313-2329-2019-27-1-102-112

9. Antimonopoly compliance for pharmaceutical companies — a fashion trend or a necessity // URL: https://pharmvestnik.ru/ content/articles/Antimonopolnyi-komplaens-dlyafarmacevticheskih-kompanii-modnyi-trend-ilineobhodimost.html (Accessed: 06.10.2021) (In Russ.)

10. Ilchenko S. S. Antimonopoly regulation of the pharmaceutical market // Strategy for the development of modern science. Part 3. M.: Pero Publishing House. 2020. P. 198—200 (In Russ.)

11. Medvedeva N. V. Antimonopoly compliance in the system of competition development //Power and governance in the East of Russia. 2019;1(86): 51—59 (In Russ.)

12. Rodionova D. N. Antimonopoly compliance as an important part of the system for preventing anticompetitive practices // BSU Bulletin. Economics and Management. 2017;3:92-100 (In Russ.), https://doi.org/10.18101/2304-4446-2017-3-92-100

13. Soloviev V. V., Yushkin S. V., Maksimov S. V. Antitrust compliance: system standardization issues // Russian Competition Law and Economy. 2021. No. 2 (26). P. 8—16 (In Russ.), https://doi.org/10.47361/2542-0259-2021-2-26-8-16

14. Tsyganov A. G. Compliance — incentive, warning or control tool? // Competition and Law. 2016;2:5-9 (In Russ.)

15. Kvanina V. V. Antitrust compliance and its legal nature // Bulletin of the South Ural State University Series “Law”. 2019;19(1):46-52 (In Russ.), https://doi.org/10.14529/law190108

16. Beygulenko S. A. Organization compliance of modern russian pharmaceutical corporations // Finansovye issledovania. 2016;1(50):12-19 (In Russ.)


Review

For citations:


Sdvizhkov M.А. Antitrust Compliance in the Pharmaceutical Industry: Problems and Prospects of Implementation. Russian competition law and economy. 2021;(4):52-59. (In Russ.) https://doi.org/10.47361/2542-0259-2021-4-28-52-59

Views: 601


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2542-0259 (Print)